News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Intercept Pharmaceuticals To Provide 2013 Update On Clinical Programs For Obeticholic Acid On January 9


1/3/2014 9:46:23 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, Jan. 2, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced that it will provide an update on the progress of its clinical development programs after the NASDAQ Market closes on January 9, 2014. This update will provide, among other items, information on the completion of the double-blind phase of the POISE trial, top line data from the OBADIAH and PESTO trials and 2014 anticipated milestones. Intercept management will conduct a conference call and audio webcast at 4:30 p.m. EDT on the same day.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES